Q4 results reinforce our positive outlook on Roche, highlighting the company's resilience and strategic advancements. Solid performance of Ocrevus and Vabysmo are key drivers of near-term top-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback